8,175 Twist Bioscience Corporation $TWST Shares Sold by Moody National Bank Trust Division

Key Points

• Moody National Bank Trust Division reduced its Twist Bioscience stake by 40.2%, selling 8,175 shares and retaining 12,141 shares valued at approximately $2.35 million.
• Twist shares fell 18.6% to $166.97 amid high volatility, despite revenue growth of 23.2% year over year to $118.38 million. The company missed quarterly EPS expectations and remains unprofitable.
• Institutional interest remains mixed: several major investors established new positions, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and a $115.27 target price.

Moody National Bank Trust Division cut its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 40.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,141 shares of the company's stock after selling 8,175 shares during the quarter. Moody National Bank Trust Division's holdings in Twist Bioscience were worth $2,346,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Twist Bioscience during the second quarter worth $600,191,000. William Blair Investment Management LLC acquired a new position in shares of Twist Bioscience during the second quarter worth $223,722,000. Bank of America Corp DE bought a new position in shares of Twist Bioscience in the 2nd quarter valued at $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter valued at $22,563,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at $19,722,000.

Twist Bioscience Trading Down 18.6%

Shares of Twist Bioscience stock traded down $38.03 during midday trading on Tuesday, reaching $166.97. The company had a trading volume of 8,532,003 shares, compared to its average volume of 1,659,115. The stock has a fifty day moving average price of $138.77 and a 200 day moving average price of $93.53. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The firm has a market cap of $10.47 billion, a PE ratio of -75.21 and a beta of 2.19. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 EPS. On average, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Eli Lilly deal supports sentiment: Twist Bioscience shares gained in the prior session after the company announced a deal with Eli Lilly, highlighting potential commercial demand for Twist’s synthetic-DNA platform and helping drive recent investor interest. Twist Bioscience stock gained after Lilly deal
• Positive Sentiment: Higher analyst target: Leerink raised its price target for TWST from $120 to $160, reflecting more favorable expectations for the company’s growth outlook. Leerink raises target for Twist Bioscience
• Positive Sentiment: Strong momentum: Twist recently reached a new 52-week high, signaling strong buying interest. Its latest quarterly revenue rose 23.2% year over year and exceeded expectations, although the company remains unprofitable and missed consensus EPS estimates. Twist Bioscience reaches a new 52-week high
• Negative Sentiment: Broad insider selling pressures the stock: CEO Emily Leproust sold 45,736 shares, while the CFO, chief accounting officer, SVP and insider Dennis Cho also sold shares. The transactions were disclosed under pre-arranged Rule 10b5-1 plans or to cover tax withholding on vested equity awards, reducing their bearish significance; however, the volume of sales can still encourage profit-taking after the stock’s rapid advance. Twist Bioscience stock down after insider selling

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TWST. Leerink Partners upped their target price on Twist Bioscience from $160.00 to $190.00 and gave the stock an "outperform" rating in a report on Tuesday, September 29th. Guggenheim boosted their price target on Twist Bioscience from $107.00 to $212.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Robert W. Baird upped their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. Evercore lowered shares of Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 price objective for the company. in a report on Monday, July 6th. Finally, Barclays lifted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 24th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $115.27.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the sale, the insider directly owned 63,789 shares in the company, valued at approximately $12,048,466.32. The trade was a 12.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the business's stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the completion of the transaction, the senior vice president directly owned 106,632 shares in the company, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 597,309 shares of company stock worth $92,690,311 over the last quarter. 3.08% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation NASDAQ: TWST is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.